Illumina responds to EC Grail divestiture order

Illumina Inc. (ILMN) responded Friday to an order it received Thursday from the European Commission directing the company to divest its $7.1 billion acquisition of cancer-test maker Grail. Illumina said it has 12 months to divest Grail, with a potential three-month extension, and "will be permitted to explore a range of structures including, but not limited to, a third-party sale or a capital markets transaction." The company said in a statement it was committed to resolving all issues in a timely manner. "Notably, the terms of the order provide for flexibility in transaction structure, an encouraging outcome from Illumina's ongoing dialogue with the EC," Illumina said. Illumina shares declined 0.7% in Friday trading.

-Wallace Witkowski

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

10-13-23 1427ET

Copyright (c) 2023 Dow Jones & Company, Inc.